Paredes R - Search Results

1

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV.

MacDonald DM, Samorodnitsky S, Wendt CH, Baker JV, Collins G, Kruk M, Lock EF, Paredes R, Poongulali S, Weise DO, Winston A, Wood R, Kunisaki KM; INSIGHT START Pulmonary Substudy Group. MacDonald DM, et al. Among authors: paredes r. Sci Rep. 2023 Mar 23;13(1):4749. doi: 10.1038/s41598-023-29739-x. Sci Rep. 2023. PMID: 36959289 Free PMC article.

2

[Association between post-initial remission and HLA phenotype in Type I diabetics].

García-Mayor RV, Andrade A, del Pozo M, Paredes R, Pérez Méndez LF, Páramo C, Galofre JC, Luna R. García-Mayor RV, et al. Among authors: paredes r. An Med Interna. 1992 Jul;9(7):327-30. An Med Interna. 1992. PMID: 1633235 Spanish.

3

The potential role of interleukin-2 in patients with HIV infection.

Paredes R, López Benaldo de Quirós JC, Fernández-Cruz E, Clotet B, Lane HC. Paredes R, et al. AIDS Rev. 2002 Jan-Mar;4(1):36-40. AIDS Rev. 2002. PMID: 11998783 Review.

4

New antiretroviral drugs and approaches to HIV treatment.

Paredes R, Clotet B. Paredes R, et al. AIDS. 2003;17 Suppl 4:S85-96. doi: 10.1097/00002030-200317004-00010. AIDS. 2003. PMID: 15080184 Review. No abstract available.

5

[Duration of antiretroviral combinations].

Paredes R, Clotet B. Paredes R, et al. Med Clin (Barc). 2004 May 15;122(18):696-7. doi: 10.1016/s0025-7753(04)74359-6. Med Clin (Barc). 2004. PMID: 15171830 Spanish. No abstract available.

6

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.

Negredo E, Bonjoch A, Paredes R, Puig J, Clotet B. Negredo E, et al. Among authors: paredes r. Clin Infect Dis. 2005 Sep 15;41(6):901-5. doi: 10.1086/432879. Epub 2005 Aug 15. Clin Infect Dis. 2005. PMID: 16107993 Clinical Trial.

7

Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.

Bonjoch A, Paredes R, Domingo P, Cervantes M, Pedrol E, Ribera E, Force L, Llibre JM, Vilaró J, Dalmau D, Cucurull J, Mascaró J, Masabeu A, Pérez-Alvarez N, Puig J, Cinquegrana D, Clotet B. Bonjoch A, et al. Among authors: paredes r. AIDS Res Hum Retroviruses. 2006 Apr;22(4):321-9. doi: 10.1089/aid.2006.22.321. AIDS Res Hum Retroviruses. 2006. PMID: 16623634

8

Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.

Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, Tambussi G, Llibre JM, Martínez-Picado J, Vidal F, Fumaz CR, Clotet B; TIBET Study Group. Ruiz L, et al. Among authors: paredes r. AIDS. 2007 Jan 11;21(2):169-78. doi: 10.1097/QAD.0b013e328011033a. AIDS. 2007. PMID: 17197807 Clinical Trial.

9

Clinical approach to drug resistance interpretation: expert advice.

Clotet B, Paredes R. Clotet B, et al. Among authors: paredes r. Curr Opin HIV AIDS. 2007 Mar;2(2):145-9. doi: 10.1097/COH.0b013e32801470f6. Curr Opin HIV AIDS. 2007. PMID: 19372880

10

Clinical management of HIV-1 resistance.

Paredes R, Clotet B. Paredes R, et al. Antiviral Res. 2010 Jan;85(1):245-65. doi: 10.1016/j.antiviral.2009.09.015. Epub 2009 Oct 4. Antiviral Res. 2010. PMID: 19808056 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

719 results

Search Page